Chester County News and Community Website
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced its financial results for the fourth quarter and fiscal year 2024, alongside key updates on its MOLBREEVI program, which aims to address …
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced a strategic loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), for up to $200 million. This financing strengthens Savara’s resources …
Savara Secures $200 Million Loan Agreement with Hercules Capital Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the completion of its Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for MOLBREEVI, a potential treatment …
Savara Completes BLA Submission for MOLBREEVI to Treat aPAP Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has introduced the aPAP ClearPath Dried Blood Spot (DBS) Test in the United States, offering a groundbreaking solution for diagnosing autoimmune pulmonary alveolar proteinosis …
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced that its management team will participate in the upcoming Leerink Global Healthcare Conference. The company will be featured in a fireside chat …
Savara Inc. to Present at Leerink Global Healthcare Conference Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the grant of inducement equity awards to five new employees as part of its strategy to attract top talent to the organization. …
Savara Inc. Awards Stock Options and RSUs to New Employees Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the publication of a manuscript detailing long-term outcomes for molgramostim inhalation solution in patients with autoimmune pulmonary alveolar proteinosis (aPAP). The study, …
Savara Inc. Publishes Promising Long-Term Outcomes for aPAP Treatment Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced its participation in two prominent healthcare investor conferences this February. Members of the company’s management team will engage in fireside chats at …
Savara Inc. to Present at Upcoming Healthcare Investor Conferences Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the issuance of inducement awards to five newly hired employees as part of its ongoing efforts to attract top talent. The awards …
Savara Inc. Grants Inducement Awards to New Employees Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI, a potential …
Savara Begins FDA Submission for Rare Lung Disease Treatment Read More